Compare Global Payments Inc (GPN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Inovio Pharmaceuticals Inc — how do they compare? Global Payments Inc trades at $80.48 (market cap $21.40B), while Inovio Pharmaceuticals Inc trades at $1.12 (market cap $96.26M). The key difference: Global Payments Inc is far larger — about 222.3× Inovio Pharmaceuticals Inc's market cap, and Global Payments Inc pays a 1.28% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GPN | INO | |
|---|---|---|
Market Cap | $21.40B | $96.26M |
Sector | Industrials | Health |
52-Week High | $90.01 | $2.87 |
52-Week Low | $62.47 | $1.05 |
Enterprise Value | $39.11B | $67.27M |
Dividend Yield | 1.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $79.67, up 4.98% today, with a bullish technical outlook and strong earnings beats in recent quarters. The company shows robust operating cash flow of $2.66B in 2025 and benefits from strategic initiatives like the Worldpay integration and AI-powered POS expansions. However, net income margin turned negative at -7.97% for 2026, reflecting margin pressures amid rising costs and competitive fintech landscape.
GPN presents a mixed outlook: analyst consensus is bullish with a $81.56 price target (58% buy ratings), but investors face risks from debt growth (debt-to-asset ratio rising to 41.57% in 2025) and profitability challenges. Near-term catalysts include continued execution on commerce technology deals, while volatility may persist from macroeconomic headwinds.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
